创新临床试验设计与实施:技能护理与辅助生活机构中的3期COVID-19暴露后预防研究(BLAZE-2)
BLAZE-2试验由Lilly与美国国家过敏和传染病研究所合作开展,旨在评估单克隆抗体bamlanivimab(LY3819253)在技能护理与辅助生活机构中预防SARS-CoV-2感染及COVID-19(定义为症状性感染)的疗效与安全性。该研究为3期随机、双盲、安慰剂对照试验,参与者随机接受bamlanivimab(4200 mg)或安慰剂,随访24周。本文描述了研究设计、机构选择的分析方法及创新运营模式(移动研究单元)。
要点
- BLAZE-2为3期随机双盲安慰剂对照试验,评估bamlanivimab预防COVID-19。
- 研究对象为技能护理与辅助生活机构居民,随机接受4200 mg bamlanivimab或安慰剂,随访24周。
- 采用移动研究单元在机构内完成随机化与给药,应对大流行期间的运营挑战。
核心结论
- 本文描述BLAZE-2试验的设计、机构选择分析及创新运营模式,旨在评估bamlanivimab在技能护理与辅助生活机构中预防SARS-CoV-2感染和COVID-19的疗效与安全性。
研究设计与样本
- 3期随机、双盲、安慰剂对照试验,参与者随机接受bamlanivimab(4200 mg)或安慰剂,随访24周。
- 由Lilly与美国国家过敏和传染病研究所合作开展,在技能护理和辅助生活机构中进行。
关键数值与推荐
- bamlanivimab剂量为4200 mg,随访24周。
- 主要预防终点为SARS-CoV-2感染和COVID-19(定义为症状性感染)。
临床怎么用
- 采用移动研究单元在技能护理和辅助生活机构内完成随机化和给药,以应对大流行期间的运营挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The efficient community spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in the current pandemic of coronavirus disease-2019 (COVID-19), which in severe and critical cases results in progressive pulmonary infection, complicated by respiratory failure, with a high prevalence of acute respiratory distress syndrome. Of all age groups, older adults have the greatest risk of severe COVID-19 and the associated complications. Globally, there are many reports of the rapid spread of COVID-19 among residents of skilled nursing facilities, with high associated rates of morbidity and mortality. With over 1.3 million residents in nursing home care in the USA, there is an urgent need for therapeutic strategies to prevent COVID-19 in these populations.Lilly, in collaboration with the National Institute of Allergy and Infectious Diseases, conducted the BLAZE-2 trial to evaluate the efficacy and safety of the monoclonal antibody bamlanivimab (LY3819253) in preventing SARS-CoV-2 infection and COVID-19, defined as symptomatic infection, in skilled nursing and assisted living facilities. It is a phase 3 randomized, double-blind, placebo-controlled trial, where participants were randomized to bamlanivimab (4200 mg) or placebo and then followed up for 24 weeks. Conducting a trial in the midst of a pandemic in these facilities poses several challenges, including a vulnerable elderly population, travel restrictions, supply chain interruptions, and defining the target population. The operational challenges were addressed by the innovative use of mobile research units which are customized, equipped, and staffed to support BLAZE-2 randomization and participant dosing within the skilled nursing and assisted living facilities. Herein, we describe the design of the study, the analytics behind facility selection, and an innovative operational model.
引用
- Knorr J, Tuttle JL, Sabo JA, et al. Innovative clinical trial design and delivery: a phase 3 COVID-19 post-exposure prophylaxis study in skilled nursing and assisted living facilities (BLAZE-2). Trials. 2021. PMID: 34674750. doi:10.1186/s13063-021-05699-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。